Clinical Trial

Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment

Study acronym: REAL-NADIM
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This is an observational, prospective, multicentre and nationwide study. The study enroll resectable stage IIIA non-small cell lung cancer patients that are going to receive neoadjuvant treatment in real world. The primary objective of this study is evaluating whether there is a significant association between ctDNA clearance (no detection of ctDNA) after neoadjuvant treatment and before surgery and progression free survival.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-05-16; most recent amendment 2025-11-17.
Status change: Recruiting → Active, Not Recruiting 2025-11-17
Status change: Not Yet Recruiting → Recruiting 2022-07-28
Trial Details
NCT Number NCT05382052
Lead Sponsor Fundación GECP
Conditions Non Small Cell Lung Cancer Stage III, Neoadjuvant Treatment
Enrollment 100 participants
Start Date 2022-06-17
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-11-19